Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Shares Sold by PDT Partners LLC

PDT Partners LLC reduced its holdings in shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) by 85.0% during the 4th quarter, HoldingsChannel reports. The institutional investor owned 8,485 shares of the biopharmaceutical company’s stock after selling 48,250 shares during the quarter. PDT Partners LLC’s holdings in Agios Pharmaceuticals were worth $279,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Summit Investment Advisors Inc. grew its stake in shares of Agios Pharmaceuticals by 7.1% during the fourth quarter. Summit Investment Advisors Inc. now owns 5,913 shares of the biopharmaceutical company’s stock worth $194,000 after acquiring an additional 394 shares during the last quarter. Federated Hermes Inc. grew its position in Agios Pharmaceuticals by 4.4% during the 4th quarter. Federated Hermes Inc. now owns 13,691 shares of the biopharmaceutical company’s stock worth $450,000 after purchasing an additional 582 shares during the last quarter. KBC Group NV increased its stake in Agios Pharmaceuticals by 30.5% during the 4th quarter. KBC Group NV now owns 2,615 shares of the biopharmaceutical company’s stock valued at $86,000 after purchasing an additional 611 shares in the last quarter. Alliancebernstein L.P. raised its holdings in shares of Agios Pharmaceuticals by 1.2% in the fourth quarter. Alliancebernstein L.P. now owns 61,500 shares of the biopharmaceutical company’s stock worth $2,021,000 after buying an additional 708 shares during the last quarter. Finally, Atria Investments Inc lifted its stake in shares of Agios Pharmaceuticals by 6.9% during the fourth quarter. Atria Investments Inc now owns 11,365 shares of the biopharmaceutical company’s stock worth $373,000 after buying an additional 737 shares during the period.

Agios Pharmaceuticals Price Performance

Shares of NASDAQ AGIO opened at $30.10 on Friday. The firm’s 50 day simple moving average is $29.81 and its 200-day simple moving average is $37.84. Agios Pharmaceuticals, Inc. has a 12 month low of $23.42 and a 12 month high of $62.58. The stock has a market capitalization of $1.74 billion, a price-to-earnings ratio of 2.65 and a beta of 0.83.

Agios Pharmaceuticals (NASDAQ:AGIO) last posted its quarterly earnings data on Thursday, May 1st. The biopharmaceutical company reported ($1.55) EPS for the quarter, beating analysts’ consensus estimates of ($1.80) by $0.25. Agios Pharmaceuticals had a negative return on equity of 2.51% and a net margin of 1,845.92%. Analysts anticipate that Agios Pharmaceuticals, Inc. will post -6.85 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, Director Jacqualyn A. Fouse sold 7,497 shares of the business’s stock in a transaction dated Thursday, April 10th. The shares were sold at an average price of $25.90, for a total transaction of $194,172.30. Following the completion of the sale, the director now owns 149,220 shares of the company’s stock, valued at $3,864,798. The trade was a 4.78 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 4.93% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

AGIO has been the topic of several research reports. HC Wainwright initiated coverage on Agios Pharmaceuticals in a research report on Monday, February 24th. They issued a “buy” rating and a $58.00 target price on the stock. StockNews.com upgraded shares of Agios Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Thursday. Finally, Scotiabank cut their price objective on shares of Agios Pharmaceuticals from $74.00 to $71.00 and set a “sector outperform” rating on the stock in a research note on Friday. Five analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. According to MarketBeat.com, Agios Pharmaceuticals presently has a consensus rating of “Moderate Buy” and an average target price of $56.00.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.